BioSpace News Archive

During the 2024 Annual Meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI2024), LED Radiofluidics Corp. (LED), a preclinical biotechnology company dedicated to developing efficient PET radiotracers, and...

Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health (“NYSDOH”) approved the Company’s TR8™ PGx (“TR8") pharmacogenomic (PGx) testing service.

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02).

Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, has partnered with Polestar Technologies, a leader in optical sensing technologies since 1993, specializing in the monitoring of O2, CO2 and pH.

Pressure BioSciences, Inc. announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

Brenus Pharma, French biotech developing its proprietary discovery platform: “Stimulated-Tumor-Cell”, has presented the study design of “BreAK-CRC” First-in-human of STC-1010, Brenus’ lead candidate, during ASCO annual meeting - Trials in Progress poster session, in Chicago.

Voyager Therapeutics, Inc., a biotechnology company dedicated to advancing neurogenetic medicines, announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024, at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024, at 7:00 a.m. ET.

Ocular Therapeutix, Inc. hosted an Investor Day where it highlighted excellent clinical development progress with AXPAXLI for wet age-related macular degeneration and non-proliferative diabetic retinopathy and updated its corporate strategy.

Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced that the Company’s virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site.